Chronic Urticaria, Idiopathic

Dermatology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

InflaRx
InflaRxJENA, Germany
1 program
1
CSU lower dose treatmentPhase 21 trial
Active Trials
NCT06555328Terminated73Est. Jan 2026

Trial Timeline

Clinical trial activity over time

2025
2026
InflaRxCSU lower dose treatment

Clinical Trials (1)

Total enrollment: 73 patients across 1 trials

NCT06555328InflaRxCSU lower dose treatment

Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

Start: Jan 2025Est. completion: Jan 202673 patients
Phase 2Terminated

Related Jobs in Dermatology

MSL/Senior MSL, Dermatology - Tampa, Florida

AbbVie
Remote
10h ago

(Senior) Außendienstmitarbeiter Dermatology (all genders) - Region Thüringen

AbbVie
Remote
10h ago

Regional Sales Trainer - Dermatology (Central / West Regions)

AbbVie
Remote
11h ago

Regional Sales Trainer - Dermatology (Northeast / Southeast Regions)

AbbVie
Remote
11h ago

Delegado Especialista Ventas Dermatología (Inmunología)

AbbVie
Remote
16h ago

Senior Manager, HTA, Value and Evidence (HV&E), Medical Dermatology

Pfizer
United States - New York - New York City
Yesterday
$139K - $232K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

Related Indications

Dermatitis, Atopic(42)Hidradenitis Suppurativa(30)Chronic Spontaneous Urticaria(21)Alopecia Areata(17)Hidradenitis Suppurativa (HS)(10)Vitiligo(9)Rosacea(6)Chronic Urticaria(5)Pruritus(5)Androgenetic Alopecia(5)